The liver enzyme cytochrome P450 (CYP) 2C19 is involved in the metabolism of numerous currently prescribed drugs, including platelet inhibitors (clopidogrel), anticonvulsants (diazepam, mephenytoin), antidepressants (citalopram, sertraline), proton pump inhibitors (omeprazole, pantoprazole) and anti-malaria agents (proguanil). The new PGX-CYP2C19 StripAssay covers variants *1 (wildtype), *2, *3, *4, *5, *6, *7 *8 and *17.
Differences in its enzymatic activity due to polymorphisms in the CYP2C19 gene contribute to the inter-individual variability in drug response. This can either lead to adverse reactions due to drug accumulation and toxicity or to a diminished response. Thus CYP2C19 genotyping aids in the decision about the optimal type and dosage of drug used for a specific therapy.